NCT02549937 2024-07-10A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsHutchmedPhase 1/2 Completed130 enrolled 30 charts
NCT01222767 2021-10-29Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of ChemotherapyPharmaMarPhase 2 Completed17 enrolled 20 charts
NCT02955069 2021-04-12Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)NovartisPhase 2 Completed116 enrolled 24 charts
NCT00668148 2018-07-17A Five-Tier, Open-Label Study of IMC-A12 in Advanced SarcomaEli Lilly and CompanyPhase 2 Completed113 enrolled 13 charts
NCT00958841 2016-07-26Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginNovartisPhase 2 Terminated118 enrolled 11 charts
NCT01658436 2016-05-02BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.NovartisPhase 2 Completed31 enrolled 7 charts
NCT01628913 2016-04-07Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine TumorsNovartisPhase 2 Terminated62 enrolled 7 charts
NCT00538850 2014-03-05Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainINSYS Therapeutics IncPhase 3 Completed130 enrolled 9 charts